Slide 1: Investor Presentation Q3 & 9MFY24
vig Mankindil> NVESTOR PRESENTATIO!? INVESTOR PR ITATION Q3 & IMFY24 31 January 2024
Slide 2: Safe Harbour Statement
Safe Harbour Statement The statements, are as on date and may contain forward-looking statements like the words “believe”, “expects”, “anticipate”, “aim”, “will likely result”, “would”, “will continue”, “contemplate” “intends”, “plans”, “estimates”, “seek to”, “future”, “objective”, “projects”, “goa
Slide 3: Index
Index 01 Corporate Framework 03 Business Updates • Mankind Pharma – Key Milestones • Domestic Business • Mankind Pharma at a Glance • Consumer Healthcare Business • Key Strengths • Export Business • Strategy Going Ahead 02 Financial Performance 04 Additional Information • Key Performance Indicators
Slide 4: Corporate Framework
Mankindi> Serving Lie a4 = ° s 0) £ £ LL 7) ~ £ ° a = to] Oo
Slide 5: Mankind Pharma - Key Milestones
Mankind Pharma - Key Milestones Sustained Improvement in Domestic Formulations Market Share and Ranking Market Share 4th 8th Rank Rank 4.1% 4.4% 3.3% 1995 2004 2007-10 2012 2015 2018-19 2020 2021 2022 2023 Commenced Entered chronic Entered consumer Set up first R&D Incorporated our Paonta Sahib faci
Slide 6: Mankind Pharma at a Glance
Mankind Pharma at a Glance #1 Youngest #4 4 Rank in Prescriptions Consumer Healthcare brands in Top 5 of the IPM* By value in the IPM* Market over the last five years* ranked #1 in their categories* Leadership INR 8,749 Crore 97% 22 15,000+ FY23 Revenue Domestic Revenue brands* worth INR 100 Cr+ Fie
Slide 7: Key Strengths
Key Strengths India revenues contribute 93% of revenues in 9MFY24 Focus on Focus on Net cash of INR 2,756 Cr** with consistent CFO/ domestic Strong domestic EBITDA ratio in excess of 70% during 9MFY24 business Volume- balance sheet business with best in growth driven Consistent outperformance in vol
Slide 8: Strategy Going Ahead
Strategy Going Ahead Increase the value of prescriptions in existing markets of strength by expanding market coverage; CVM moved from 62% in FY21 to 68% in 9MFY24* Increasing share of chronic segment by growing presence in existing therapies (Diabetes - Insulin Glargine, Respiratory - Inhalers) and
Slide 9: Financial Performance
ig Mankindi> Serving Life Financial Performance
Slide 10: Q3FY24 - Key Financial Snapshot
Q3FY24 - Key Financial Snapshot Financials / Capital Growth Margins Efficiency 2,607 24.7% 31.3% Revenue (INR Cr) YoY Growth ROCE* 611 / 23.4% 39.1% 26.4% EBITDA (INR Cr) / Margin YoY Growth ROE* Mr. Rajeev Juneja 460 / 17.6% 55.5% Vice Chairman & Managing Director PAT (INR Cr) / Margin YoY Growth •
Slide 11: Q3 & 9M FY24 - P&L Highlights
Q3 & 9M FY24 - P&L Highlights YoY QoQ YoY INR Crore Q3FY24 Q3FY23 Q2FY24 9MFY24 9MFY23 Growth Growth Growth Revenue from Operations 2,607 2,091 24.7% 2,708 (3.7%) 7,894 6,696 17.9% (A=B+C) Domestic Business (B) 2,400 1,996 20.2% 2,529 (5.1%) 7,348 6,481 13.4% Consumer Healthcare 149 157 (4.8%) 193 (
Slide 12: Key Financial Metrics
Key Financial Metrics ROE* ROCE* Net Cash# (INR crore) Dip on account Dip on account 34% of acquisition of acquisition 26% 31% 25% 2,756 23% 31% 23% 25% 1,366 997 412 Mar31, Mar31, Dec31, Dec31, Mar31, Mar31, Dec31, Dec31, Mar31, Mar31, Dec31, Dec31, 2022 2023 2022 2023 2022 2023 2022 2023 2022 2023
Slide 13: Business Updates
vig Mankindil> Serving Lif Business Updates
Slide 14: Domestic Business Performance
Domestic Business Performance Strong Growth in Domestic Revenue* INR Crore 8,453 7,595 7,348 6,481 1,996 2,400 FY22 FY23 9MFY23 9MFY24 Q3FY23 Q3FY24 • Domestic Business witnessed a growth of 20%* YoY in Q3FY24 supported by • Out-performance in chronic therapies (1.5x to IPM; 1.3x to IPM Chronic) • R
Slide 15: Increasing Share of Chronic Segment
Increasing Share of Chronic Segment Increased chronic share (having higher price realization and lifetime value) by 100bps in last 12 months Consistent focus to increase chronic contribution 1.3x outperformance to IPM Chronic in Q3FY24 3.5% 2.9% 1.5x 1.3x 1.4x 1.3x 38 38 38 19 37 17 35 14 13 12 12 3
Slide 16: Q3FY24 Business Update
Q3FY24 Business Update High Ranks across Acute and Chronic Areas Q3FY24 - Sales Mix representing Diversified Therapy Presence Rank in CVM FY 20-23 CAGR 3% Key Therapy Areas (Q3FY24) 8% Mankind IPM 17% 5% Anti-Infectives Cardiovascular Chronic therapies 15% 11% 5% Gastro Intestinal Respiratory Cardio
Slide 17: 9MFY24 Business Update
9MFY24 Business Update Continued outperformance to IPM 1.3x outperformance to IPM chronic in 9MFY24* 6% 7% 8% 9% 37% 34% 38% 35% 2% 4% 13.0 3% 3% 10.8 9.6 9.7 6% 5% 4% 6% 1% -2% -1% -1% IPM Mankind IPM Mankind 9MFY23 9MFY23 9MFY24 9MFY24 9MFY23 9MFY24 Volume Price New Introduction IPM Chronic Growth
Slide 18: Building Consumer Healthcare Franchise
Building Consumer Healthcare Franchise Consumer Healthcare Segment Revenue INR Crore 692 2% 589 550 540 157 149 FY22 FY23 9MFY23 9MFY24 Q3FY23 Q3FY24 • Consumer Healthcare segment revenue declined during the quarter due to • initiatives taken in last quarter towards optimization of channel inventory
Slide 19: Strong Corporate Identity Complements Brand Recall
Strong Corporate Identity Complements Brand Recall… Strategically selected national and regional brand ambassadors Corporate Brand Ambassadors Dominant Brands Consumer Healthcare Brand Ambassadors #1 Condom Brand Kartik Aaryan Sunny Leone Market Share – 31% #1 Anushka Kajal Srabanti Pregnancy Test K
Slide 20: …With Targeted Marketing Initiatives
…With Targeted Marketing Initiatives Continues to leverage on #ApnePartnerSePucho Campaign, promoted on various Strengthening connect with 2.6 lakh chemists through media channels personalized WhatsApp videos MEN’S DAY CAMPAIGN: Tied up with NGO SAATHI & launched “Expert Pregnancy Care Solution Bran
Slide 21: …With Targeted Marketing Initiatives
…With Targeted Marketing Initiatives Gas-O-Fast - India Ki Acidity Cultural events marketing initiatives to Ka Asli Indian Solution enhance brand visibility Outdoor branding across UP & WB (In-shop branding, train wraps, Leveraged celebrity endorsement across Visibility and brand building railway st
Slide 22: Exports Business Update
Exports Business Update Revenue from Exports INR Crore 546 296 187 215 207 95 FY22 FY23 9MFY23 9MFY24 Q3FY23 Q3FY24 • Exports business witnessed a growth of 118% YoY in Q3FY24 and 16% QoQ aided by one-off opportunities in the US • Focus on differentiated filings, including in-licensing for key marke
Slide 23: Additional Information
ig Mankindil> y/ Additional Information
Slide 24: Key Performance Indicators (as per ICDR Requirement post IPO)
Key Performance Indicators (as per ICDR Requirement post IPO) FY22 FY23 Q3FY23 Q3FY24 9M FY23 9M FY24 Revenue from Operations within India as a percentage of revenue 97.60% 96.62% 95.46% 92.06% 96.79% 93.08% from operations % EBITDA* (INR Million) 20,038.00 19,130.61 4,394.00 6,111.09 14,936.10 19,5
Slide 25: ESG: Organization wide focus on sustainable growth
ESG : Organization* wide focus on sustainable growth Key Key Key Sustainability Excellence New Organizational Award – By Highlights Initiatives Priorities Technologies University of Petroleum and Energy Studies, Fair-2.0 • Zero Reportable Lost Time • Imparted 100 Man- • On track to achieve • Unit-1-
Slide 26: Mankind's ESG goals
Mankind’s ESG goals Environment* Hazardous Waste - 70% for Implementation of Wild life co-processing and 30% for Conservation plan for 2 nos Plastic Neutral by FY'24 landfilling by 2027 (Base of Schedule-1 species in year FY'21) Sotanala area 100% Renewable Power Reduce ground water Carbon neutral b
Slide 27: Financials - Steady growth trajectory
Financials - Steady growth trajectory Revenue (INR Cr) Strong Growth in Domestic Revenue Revenue from Exports (INR crore) 14% 14% CAGR CAGR 8,749 7,782 7,894 8,453 6,696 7,595 7,348 57% 5,865 6,214 6,481 CAGR 5,789 6,028 546 296 186 187 215 76 FY20 FY21 FY22 FY23 9MFY23 9MFY24 FY20 FY21 FY22 FY23 9M
Slide 28: Key Performance Highlights
Key Performance Highlights Key Performance Highlights FY18 FY19 FY20 FY21 FY22 FY23 Value Growth YoY in IPM (%) 11.3 12.6 12.5 11.1 17.7 10.6 Market share by Value in IPM (%) 3.9 4.0 4.1 4.3 4.3 4.4 Market Ranking by Value in IPM (x) 4 4 4 4 4 4 CVM share in total IPM (%) 60.2 61.6 62.4 62.2 65.4 68
Slide 29: Sales Mix Trends
Sales Mix Trends Therapy wise share in Total Revenue FY18 FY19 FY20 FY21 FY22 FY23 ANTI-INFECTIVES 17.7 15.8 15.9 13.2 14.7 15.0 CARDIAC 10.1 10.8 11.5 12.6 12.1 12.8 GASTRO INTESTINAL 12.3 11.5 11.4 11.3 10.9 10.8 RESPIRATORY 7.6 8.0 8.7 7.2 9.7 9.5 PAIN / ANALGESICS 6.0 6.4 6.1 5.4 5.4 5.0 ANTI DI
Slide 30: Shareholding Pattern
Shareholding Pattern BSE Ticker 543904 1.1% 2.3% 7.6% NSE Symbol MANKIND 12.4% Market Cap. (INR Crore)* 79,417 % Free Float 23.5 Free Float Market Cap. (INR Crore) 18,667 76.5% Shares Outstanding (Crore) 40.06 Industry Pharmaceuticals Promoters FPI & Bodies Corporate Mutual Funds Retail Others Share
Slide 31: Q3 & 9MFY24 Earnings Call Details
Q3 & 9MFY24 Earnings Call Details Date 2nd February, 2023 Time 12:00 PM IST Dial – In Details Universal Access Numbers +91 22 6280 1102 / +91 22 7115 8003 https://services.choruscall.in/DiamondPassRegistration/register?confirm Diamond Pass ationNumber=2055181&linkSecurityString=c0e972b89 31
Slide 32: Annexures
Annexures • ROE = (Profit for the year) / (average total equity less cash) o Profit excludes interest income and gain on current investments measured at FVTPL • Adjusted ROE = (Adjusted profit for the year) / (average adjusted total equity less cash) o Profit excludes any M&A related impact, interes
Slide 33: Thank You
Thank You For more information please visit our website: https://www.mankindpharma.com For specific queries, contact: Abhishek Agarwal Investor Relations – 011 – 46846700 Ext. 3532 Investor.relations@mankindpharma.com